SEVERANCE AGREEMENTSeverance Agreement • February 6th, 2009 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 9th day of January, 2009 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”) and Gregory D. Perry (the “Executive”).
AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 6th, 2009 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 3 to the Collaboration and License Agreement (this “Third Amendment”) is effective as of August 31, 2008 (the “Third Amendment Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation with a principal office at 830 Winter Street, Waltham, Massachusetts 02451 (“ImmunoGen”), and sanofi-aventis U. S. LLC, a Delaware limited liability company with a offices at 1041 Rt. 202-206, Bridgewater, NJ 08807 (“sanofi-aventis”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Collaboration and License Agreement (the “Agreement”) dated as of July 30, 2003 (the “Agreement Effective Date”) by and between ImmunoGen and Aventis Pharmaceuticals, Inc. (“Aventis”), as amended August 31, 2006 and October 11, 2007.
